STOCK TITAN

Dynavax to Present at the Stifel 2020 Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical firm focusing on vaccine development, announced that CEO Ryan Spencer will present at the Stifel 2020 Virtual Healthcare Conference on November 16 at 3:30 p.m. E.T. Investors can access the live audio webcast via the 'Events & Presentations' section on the company's website. A replay will be available for 30 days after the event. Dynavax's HEPLISAV-B® vaccine is approved for preventing hepatitis B in adults and is advancing its CpG 1018 vaccine adjuvant through various collaborations.

Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif., Nov. 2, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, at 3:30 p. m. E.T.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-stifel-2020-virtual-healthcare-conference-301165128.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax present at the Stifel 2020 Virtual Healthcare Conference?

Dynavax will present on November 16, 2020, at 3:30 p.m. E.T.

How can I access the Dynavax presentation during the conference?

The presentation can be accessed via the 'Events & Presentations' page on Dynavax's website.

What is Dynavax's stock symbol?

Dynavax's stock symbol is DVAX.

What is HEPLISAV-B® and what is its purpose?

HEPLISAV-B® is Dynavax's hepatitis B vaccine approved for preventing infection in adults.

How long will the replay of the Dynavax conference presentation be available?

The replay will be available for 30 days following the live event.

Dynavax Technologies Corporation

NASDAQ:DVAX

DVAX Rankings

DVAX Latest News

DVAX Stock Data

1.57B
131.01M
0.34%
104.56%
14.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE